Intercept Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Intercept Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Intercept Pharmaceuticals Inc Strategy Report
- Understand Intercept Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Intercept Pharmaceuticals Inc (Intercept), a subsidiary of Alfasigma SpA, is a biopharmaceutical company that discovers, develops and commercializes novel drugs for the treatment of progressive non-viral liver diseases with high unmet medical need. The company harnesses its proprietary bile acid chemistry to develop innovative drugs. Its marketed product, Ocaliva (obeticholic acid), is a bile acid analog that has a chemical structure based on naturally occurring human bile acid.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company conducts research to develop products for the treatment of chronic liver diseases with unmet medical need. It is developing drugs for indications for which there are limited or no approved therapies. Intercept's product candidates are based on its unique proprietary bile acid chemistry. In this chemistry, bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, exclusively binds and activates the farnesoid X receptor (FXR) that has broad liver-protective properties. Its pipeline products include obeticholic acid (OCA) and bezafibrate for the potential treatment of individuals with PBC and INT-787, next-generation FXR agonist for the treatment of severe alcohol-associated hepatitis (sAH).
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer